|Bid||169.95 x 800|
|Ask||176.17 x 800|
|Day's Range||171.81 - 175.65|
|52 Week Range||136.50 - 183.39|
|PE Ratio (TTM)||107.25|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
U.S. health regulators have expanded the use of one of Vertex Pharmaceuticals Inc's cystic fibrosis drugs to include patients aged between 12 months and 24 months. The expanded approval makes Kalydeco the first medicine to treat the underlying cause of the genetic disease in this age group among patients with specific mutations in the CF transmembrane regulator (CFTR) gene, Vertex said on Wednesday. The drug is currently approved in the United States to treat patients aged 2 and older whose CFTR gene has certain mutations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 14) DexCom, Inc. (NASDAQ: DXCM ) Masimo Corporation (NASDAQ: MASI ...
Shares of Bayer (BAYRY) crash as its newly acquired company Monsanto was fined $289 million over allegations that its weedkiller caused cancer.
Below is a list of notable corporate events for the week beginning August 13. Note, this list is not comprehensive and all dates are subject to change. All times are ET. View more earnings on NTAP Monday ...
In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, which was a ~66% YoY (year-over-year) growth. Exelixis’s net product revenues grew 9% sequentially in the second quarter. In the second quarter, Ipsen, Exelixis’s partner, generated cumulative revenues of $150 million from sales of cabozantinib.
Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing. Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment. Of course, the opposite can also be true - prices can fall just as quickly if data or approvals fail to impress. That's why it's so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a "Moderate Buy" or "Strong Buy") and the expected upside potential based on recent ratings. Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We'll also explore the pros' analysis and price targets for each company. SEE ALSO: The 18 Best Stocks to Buy for the Rest of 2018
Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity?
Infinity (INFI) posts narrower-than-expected loss in the second quarter of 2018 and provides update on pipeline candidate, IPI 549.
The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.
Stifel updated its outlook on the biotech sector, and sees reason to be bullish on several big names. While biotech has had its ups and downs, in general this has been a good year to be in the sector: The iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) have risen 10.7% and 12.8%, respectively, since the start of 2018, above the broader market and even the gain seen by the increasing popular health-care sector itself, as the Health Care Select Sector SPDR ETF (XLV) is up 8.8% since the start of the year. While smaller biotechs have benefited more from the moves, there are still some bigger companies that warrant attention, argues Stifel's Paul Matteis. Stifel transferred and initiated coverage on a number of biotech stocks, today, with Buy ratings on Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceuticals (BMRN), Biogen (BIIB), Alnylam Pharmaceuticals (ANLY), Sage Therapeutics (SAGE), Neurocrine Biosciences (NBIX), Wave Life Sciences (WVE), and Alder BioPharmaceuticals (ALDR).
Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. As of August 6, 19 analysts were tracking Sarepta Therapeutics stock.
Below is a list of notable corporate events for the week beginning August 6. Note, this list is not comprehensive and all dates are subject to change. All times are ET. View more earnings on AMZN Monday ...
Driving the trend are highly specialized workers who, through years of schooling and research, fill lucrative roles demanding unusual or, in many cases, unparalleled skill sets.
Privately held Celtaxsys Inc said on Thursday a mid-stage trial testing its experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not improve lung function. There are few treatment options for the 70,000 cystic fibrosis patients worldwide, who rarely live beyond 40 and possess a defective gene that leads to the build-up of thick mucus which clogs the lungs and other organs, often triggering inflammation. The company is considering private financing, a public offering and possible financial support from the Cystic Fibrosis Foundation ahead of a late-stage study set for the second half of 2019, Chief Executive Officer Greg Duncan told Reuters.
Impressive second-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Gilead Sciences could swipe its next chief executive from privately held Dermavant or seek a major merger with Vertex Pharmaceuticals or Dow Jones' Pfizer, investors suggested.